call_id,hcp_id,rep_id,call_date,call_note_raw,call_summary_target,agent_summary,agent_sentiment,agent_topics,agent_next_action,agent_compliance_flag,agent_competitor_flag
CALL_000000,HCP_00476,REP_048,2024-01-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,"HCP discussed patient support program and study results, showing low interest.",Low,"Patient Support Program, Efficacy",Send clinical reprint,False,False
CALL_000001,HCP_01280,REP_079,2024-06-27,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,"HCP discussed new indication and study results, aligned on providing starter kits.",Medium,"New Indication, Efficacy",Provide starter kits,False,False
CALL_000002,HCP_00124,REP_022,2024-03-04,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,"HCP discussed new indication, prefers competitor, and is interested in copay info.",Medium,"New Indication, Efficacy",Share copay info,False,True
CALL_000003,HCP_02237,REP_045,2024-03-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,"HCP discussed access/prior auth, mentioned competitor, and showed low interest in product.",Low,"Access / Prior Auth, Efficacy",Schedule follow-up visit,False,True
CALL_000004,HCP_00220,REP_041,2024-02-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.,"HCP discussed safety concerns and study results, awaiting formulary decision.",High,Safety,Wait for formulary decision,False,False
CALL_000005,HCP_02729,REP_078,2024-01-19,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,"HCP discussed patient support program, formulary restrictions, and study results with low interest level.",Low,"Patient Support Program, Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000006,HCP_01923,REP_072,2024-01-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,"HCP discussed access and prior auth issues, and showed high interest in the product.",High,"Access / Prior Auth, Efficacy",Share copay info,False,False
CALL_000007,HCP_02786,REP_068,2024-04-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.,HCP discussed patient support program and study results with low interest level.,Low,"Patient Support Program, Efficacy",Provide starter kits,False,False
CALL_000008,HCP_00205,REP_036,2024-01-18,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,"HCP discussed efficacy improvement and cost concerns, showing low interest.",Low,"Efficacy, Other",Connect with MSL,False,False
CALL_000009,HCP_03659,REP_013,2024-03-19,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,"HCP discussed efficacy improvement and cost concerns, with low interest level.",Low,"Efficacy, Other",Schedule follow-up visit,False,False
CALL_000010,HCP_00456,REP_066,2024-01-16,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.,HCP discussed patient support program and study results with high interest level,High,"Patient Support Program, Efficacy",Schedule follow-up visit,False,False
CALL_000011,HCP_01801,REP_024,2024-07-12,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,"HCP discussed new indication and study results, showing medium interest.",Medium,"New Indication, Efficacy",Connect with MSL,False,False
CALL_000012,HCP_03729,REP_017,2024-03-03,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,"HCP discussed access and prior auth issues, and aligned on providing starter kits.",Medium,"Access / Prior Auth, Efficacy",Provide starter kits,False,False
CALL_000013,HCP_02568,REP_048,2024-01-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.,"HCP discussed new indication and study results, showing high interest in the product.",High,"New Indication, Efficacy",Provide starter kits,False,False
CALL_000014,HCP_04494,REP_005,2024-01-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.,"HCP discussed patient support program, study results, and expressed medium interest in the product.",Medium,"Patient Support Program, Efficacy",Send clinical reprint,False,False
CALL_000015,HCP_02329,REP_025,2024-01-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,"HCP discussed efficacy improvement and workflow complexity, awaiting formulary decision.",Medium,"Efficacy, Access / Prior Auth",Wait for formulary decision,False,False
CALL_000016,HCP_03388,REP_071,2024-01-06,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.,"HCP discussed efficacy improvement and study results, showing low interest in the product.",Low,Efficacy,Share copay info,False,False
CALL_000017,HCP_01025,REP_057,2024-04-24,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.,HCP discussed patient support program and study results with low interest level.,Low,"Patient Support Program, Efficacy",Provide starter kits,False,False
CALL_000018,HCP_03729,REP_050,2024-03-14,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.,HCP discussed new indication and expressed high interest in the product.,High,"New Indication, Efficacy",Connect with MSL,False,False
CALL_000019,HCP_04286,REP_027,2024-01-26,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,"HCP discussed access/prior auth and study results, showing medium interest in the product.",Medium,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000020,HCP_04780,REP_026,2024-01-17,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.,"HCP discussed patient support program and study results, showing high interest in the product.",High,"Patient Support Program, Efficacy",Connect with MSL,False,False
CALL_000021,HCP_04368,REP_020,2024-01-07,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.,HCP discussed efficacy improvement and study results with low interest level,Low,Efficacy,Send clinical reprint,False,False
CALL_000022,HCP_02425,REP_052,2024-01-31,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.,"HCP discussed side effect management, cost, and study results, with low interest in the product.",Low,"Safety, Access / Prior Auth",Provide starter kits,True,False
CALL_000023,HCP_01081,REP_063,2024-01-18,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.,"HCP discussed side effect management, preferred competitor, and shared study results.",Medium,"Safety, Efficacy",Share copay info,True,True
CALL_000024,HCP_01096,REP_051,2024-01-14,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,"HCP discussed access and prior auth issues, and showed medium interest in the product.",Medium,"Access / Prior Auth, Efficacy",Schedule follow-up visit,False,False
CALL_000025,HCP_03299,REP_004,2024-01-04,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.,"HCP discussed access/prior auth and study results, showing low interest in the product.",Low,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000026,HCP_04844,REP_030,2024-02-28,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.,"HCP discussed patient support program, formulary restrictions, and study results, aligning on providing starter kits.",Medium,"Patient Support Program, Access / Prior Auth, Efficacy",Provide starter kits,False,False
CALL_000027,HCP_00971,REP_044,2024-01-24,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.,"HCP discussed side effect management, workflow complexity, and study results with low interest level.",Low,"Safety, Efficacy",Share copay info,True,False
CALL_000028,HCP_00731,REP_047,2024-01-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.,HCP discussed patient support program and study results with low interest level.,Low,"Patient Support Program, Efficacy",Connect with MSL,False,False
CALL_000029,HCP_02002,REP_029,2024-01-22,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.,"HCP discussed side effect management and needs more data, showed low interest in the product.",Low,"Safety, Efficacy",Share copay info,True,False
CALL_000030,HCP_04521,REP_045,2024-01-29,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.,"HCP discussed access/prior auth and study results, showing low interest in the product.",Low,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000031,HCP_00844,REP_046,2024-01-06,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,"HCP discussed new indication, mentioned high cost, and showed high interest in the product.",High,"New Indication, Efficacy",Send clinical reprint,False,False
CALL_000032,HCP_00121,REP_008,2024-01-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,"HCP discussed safety concerns, formulary restrictions, and study results, with a medium interest level in the product.",Medium,"Safety, Access / Prior Auth",Share copay info,False,False
CALL_000033,HCP_03584,REP_018,2024-01-30,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,"HCP discussed access and prior auth issues, and showed medium interest in the product.",Medium,"Access / Prior Auth, Efficacy",Share copay info,False,False
CALL_000034,HCP_04421,REP_040,2024-02-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.,HCP discussed new indication and workflow complexity with low interest level.,Low,"New Indication, Efficacy",Schedule follow-up visit,False,False
CALL_000035,HCP_03399,REP_065,2024-05-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.,"HCP discussed safety concerns and workflow complexity, with low interest in the product.",Low,"Safety, Access / Prior Auth",Wait for formulary decision,False,False
CALL_000036,HCP_01443,REP_033,2024-01-11,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,"HCP discussed safety concerns, formulary restrictions, and study results, with a medium interest level in the product.",Medium,"Safety, Access / Prior Auth",Connect with MSL,False,False
CALL_000037,HCP_00009,REP_051,2024-04-20,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.,"HCP discussed new indication, prefers competitor, and is interested in starter kits.",High,"New Indication, Efficacy",Provide starter kits,False,True
CALL_000038,HCP_01826,REP_036,2024-02-03,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.,"HCP discussed side effect management, mentioned competitor, and showed medium interest in the product.",Medium,"Safety, Efficacy",Share copay info,True,True
CALL_000039,HCP_02969,REP_042,2024-02-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,"HCP discussed side effect management, formulary restrictions, and study results, with low interest in the product.",Low,"Safety, Access / Prior Auth",Wait for formulary decision,True,False
CALL_000040,HCP_04837,REP_025,2024-02-23,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.,"HCP discussed side effect management and study results, with low interest in the product.",Low,"Safety, Efficacy",Provide starter kits,True,False
CALL_000041,HCP_04168,REP_000,2024-01-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.,"HCP discussed access/prior auth and study results, awaiting formulary decision with high interest.",High,"Access / Prior Auth, Efficacy",Wait for formulary decision,False,False
CALL_000042,HCP_02883,REP_029,2024-02-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.,"HCP discussed efficacy improvement and formulary restrictions, aligning on sending clinical reprint.",High,"Efficacy, Access / Prior Auth",Send clinical reprint,False,False
CALL_000043,HCP_01933,REP_035,2024-01-20,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.,HCP discussed patient support program and study results with high interest level.,High,"Patient Support Program, Efficacy",Send clinical reprint,False,False
CALL_000044,HCP_03201,REP_013,2024-01-31,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,"HCP discussed access and prior auth issues, and showed medium interest in the product.",Medium,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000045,HCP_00130,REP_073,2024-02-06,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.,"HCP discussed patient support program, study results, and competitor preference with medium interest level.",Medium,"Patient Support Program, Efficacy",Connect with MSL,False,True
CALL_000046,HCP_00839,REP_028,2024-06-08,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.,HCP discussed efficacy improvement and study results with high interest level.,High,Efficacy,Share copay info,False,False
CALL_000047,HCP_01369,REP_053,2024-02-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.,HCP discussed efficacy improvement and workflow complexity with low interest level.,Low,"Efficacy, Other",Share copay info,False,False
CALL_000048,HCP_03796,REP_056,2024-01-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.,"HCP discussed efficacy improvement and needs more data, awaiting formulary decision.",High,Efficacy,Wait for formulary decision,False,False
CALL_000049,HCP_04326,REP_070,2024-01-29,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,"HCP discussed access and prior auth, and showed high interest in the product.",High,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000050,HCP_00376,REP_016,2024-03-20,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.,"HCP discussed patient support program and study results, aligned on providing starter kits.",Medium,"Patient Support Program, Efficacy",Provide starter kits,False,False
CALL_000051,HCP_04302,REP_012,2024-01-31,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,"HCP discussed efficacy improvement and cost concerns, aligned on sharing copay information.",Medium,"Efficacy, Access / Prior Auth",Share copay info,False,False
CALL_000052,HCP_01478,REP_064,2024-02-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.,"HCP discussed new indication, cost concerns, and study results, with low interest in the product.",Low,"New Indication, Efficacy",Wait for formulary decision,False,False
CALL_000053,HCP_03683,REP_000,2024-01-09,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.,HCP discussed efficacy improvement and workflow complexity with low interest level.,Low,Efficacy,Schedule follow-up visit,False,False
CALL_000054,HCP_01281,REP_055,2024-03-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.,"HCP discussed safety concerns and high cost, with low interest in the product.",Low,"Safety, Access / Prior Auth",Send clinical reprint,False,False
CALL_000055,HCP_00511,REP_071,2024-04-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.,"HCP discussed side effect management, workflow complexity, and study results, with high interest in the product.",High,"Safety, Efficacy",Send clinical reprint,True,False
CALL_000056,HCP_04702,REP_079,2024-03-18,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.,"HCP discussed safety concerns, formulary restrictions, and study results, with high interest in the product.",High,"Safety, Access / Prior Auth",Share copay info,False,False
CALL_000057,HCP_02278,REP_063,2024-01-20,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,HCP raised safety concern and discussed study results,High,"Safety, Efficacy",Share copay info,False,False
CALL_000058,HCP_01684,REP_020,2024-01-17,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,"HCP discussed patient support program and study results, awaiting formulary decision.",Medium,"Patient Support Program, Efficacy",Wait for formulary decision,False,False
CALL_000059,HCP_00585,REP_052,2024-01-17,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,"HCP discussed efficacy improvement and needs more data, awaiting formulary decision.",Low,Efficacy,Wait for formulary decision,False,False
CALL_000060,HCP_01417,REP_063,2024-02-04,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.,"HCP discussed new indication, formulary restrictions, and study results with low interest level.",Low,"New Indication, Access / Prior Auth, Efficacy",Provide starter kits,False,False
CALL_000061,HCP_00516,REP_023,2024-02-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.,"HCP discussed efficacy improvement and cost concerns, aligning on sending clinical reprints.",High,"Efficacy, Other",Send clinical reprint,False,False
CALL_000062,HCP_03392,REP_005,2024-04-26,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.,"HCP discussed access/prior auth and study results, showing medium interest.",Medium,"Access / Prior Auth, Efficacy",Share copay info,False,False
CALL_000063,HCP_04003,REP_010,2024-01-24,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.,"HCP discussed patient support program and study results, showing low interest in the product.",Low,"Patient Support Program, Efficacy",Wait for formulary decision,False,False
CALL_000064,HCP_00708,REP_066,2024-01-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,HCP raised safety concern and discussed study results with high interest level.,High,"Safety, Efficacy",Connect with MSL,False,False
CALL_000065,HCP_00240,REP_011,2024-02-02,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.,"HCP discussed patient support program and study results, showing high interest in the product.",High,"Patient Support Program, Efficacy",Schedule follow-up visit,False,False
CALL_000066,HCP_00361,REP_009,2024-06-14,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.,HCP discussed access/prior auth and study results with low interest in the product.,Low,"Access / Prior Auth, Efficacy",Connect with MSL,False,False
CALL_000067,HCP_03348,REP_011,2024-01-29,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.,HCP discussed efficacy improvement and aligned on providing starter kits.,High,Efficacy,Provide starter kits,False,False
CALL_000068,HCP_00134,REP_027,2024-01-30,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.,"HCP discussed side effect management, workflow complexity, and study results, with a medium interest level in the product.",Medium,"Safety, Efficacy",Wait for formulary decision,False,False
CALL_000069,HCP_04412,REP_076,2024-02-17,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,"HCP discussed access/prior auth and study results, showing medium interest.",Medium,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000070,HCP_02277,REP_038,2024-03-28,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,"HCP discussed side effect management, formulary restrictions, and study results with low interest in the product.",Low,"Safety, Access / Prior Auth, Efficacy",Share copay info,True,False
CALL_000071,HCP_03994,REP_053,2024-01-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.,HCP discussed access/prior auth and study results with low interest level.,Low,"Access / Prior Auth, Efficacy",Share copay info,False,False
CALL_000072,HCP_03301,REP_024,2024-01-28,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.,"HCP discussed new indication, formulary restrictions, and study results with low interest level.",Low,"New Indication, Access / Prior Auth, Efficacy",Share copay info,False,False
CALL_000073,HCP_01137,REP_013,2024-02-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,"HCP discussed access/prior auth and study results, awaiting formulary decision.",Medium,"Access / Prior Auth, Efficacy",Wait for formulary decision,False,False
CALL_000074,HCP_00955,REP_066,2024-02-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,"HCP discussed patient support program and study results, showing medium interest.",Medium,"Patient Support Program, Efficacy",Share copay info,False,False
CALL_000075,HCP_00833,REP_051,2024-01-03,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,"HCP discussed side effect management and formulary restrictions, showing low interest in the product.",Low,"Safety, Access / Prior Auth",Wait for formulary decision,False,False
CALL_000076,HCP_02249,REP_023,2024-02-12,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.,"HCP discussed access/prior auth and study results, showing high interest in the product.",High,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000077,HCP_02810,REP_002,2024-04-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.,"HCP discussed side effect management and study results, showing low interest in the product.",Low,"Safety, Efficacy",Connect with MSL,False,False
CALL_000078,HCP_00577,REP_006,2024-01-29,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,"HCP discussed access/prior auth and study results, showing medium interest.",Medium,"Access / Prior Auth, Efficacy",Send clinical reprint,False,False
CALL_000079,HCP_03768,REP_045,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.,"HCP discussed safety concerns and formulary restrictions, with low interest in the product.",Low,"Safety, Access / Prior Auth",Provide starter kits,False,False
CALL_000080,HCP_02350,REP_061,2024-02-21,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.,"HCP discussed side effect management, cost, and study results, showing high interest in the product.",High,"Safety, Efficacy",Connect with MSL,True,False
CALL_000081,HCP_02779,REP_054,2024-02-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.,"HCP discussed side effect management, prefers competitor, and has low interest in the product.",Low,"Safety, Efficacy",Send clinical reprint,True,True
CALL_000082,HCP_00834,REP_011,2024-01-20,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,"HCP discussed patient support program, formulary restrictions, and study results with low interest level.",Low,"Patient Support Program, Access / Prior Auth, Efficacy",Connect with MSL,False,False
CALL_000083,HCP_01085,REP_038,2024-01-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.,"HCP discussed access/prior auth, study results, and competitor preference with high interest",High,"Access / Prior Auth, Efficacy",Schedule follow-up visit,False,True
CALL_000084,HCP_02895,REP_046,2024-01-18,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,"HCP discussed patient support program and study results, showing medium interest.",Medium,"Patient Support Program, Efficacy",Share copay info,False,False
CALL_000085,HCP_04487,REP_000,2024-01-12,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,"HCP discussed safety concerns, formulary restrictions, and study results, with a medium interest level in the product.",Medium,"Safety, Access / Prior Auth",Provide starter kits,False,False
CALL_000086,HCP_00092,REP_063,2024-04-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,"HCP discussed patient support program and study results, aligned on providing starter kits with low interest level.",Low,"Patient Support Program, Efficacy",Provide starter kits,False,False
CALL_000087,HCP_02336,REP_060,2024-02-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,"HCP discussed efficacy improvement and needs more data, with low interest level.",Low,Efficacy,Connect with MSL,False,False
CALL_000088,HCP_00546,REP_011,2024-01-13,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.,"HCP discussed new indication, formulary restrictions, and study results, showing high interest in the product.",High,"New Indication, Access / Prior Auth, Efficacy",Share copay info,False,False
CALL_000089,HCP_03956,REP_053,2024-03-09,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.,"HCP discussed side effect management and needs more data, shared copay info.",Medium,"Safety, Efficacy",Share copay info,False,False
CALL_000090,HCP_03954,REP_052,2024-01-31,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,"HCP discussed new indication, mentioned competitor, and showed low interest in the product.",Low,"New Indication, Efficacy",Schedule follow-up visit,False,True
CALL_000091,HCP_02931,REP_070,2024-03-28,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.,"HCP discussed side effect management and needs more data, shared copay info.",Medium,"Safety, Efficacy",Share copay info,False,False
CALL_000092,HCP_04658,REP_040,2024-01-19,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.,"HCP discussed new indication, workflow complexity, and study results, showing high interest.",High,"New Indication, Efficacy",Connect with MSL,False,False
CALL_000093,HCP_02336,REP_017,2024-03-14,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,"HCP discussed patient support program and study results, aligned on providing starter kits.",High,"Patient Support Program, Efficacy",Provide starter kits,False,False
CALL_000094,HCP_02064,REP_008,2024-01-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.,"HCP discussed safety concerns and high cost, with high interest level in the product.",High,"Safety, Access / Prior Auth",Schedule follow-up visit,False,False
CALL_000095,HCP_02715,REP_059,2024-01-03,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.,"HCP discussed patient support program and study results, showing medium interest.",Medium,"Patient Support Program, Efficacy",Share copay info,False,True
CALL_000096,HCP_03844,REP_010,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,"HCP discussed efficacy improvement and cost concerns, aligning on sending clinical reprint.",Medium,"Efficacy, Access / Prior Auth",Send clinical reprint,False,False
CALL_000097,HCP_04738,REP_066,2024-01-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.,"HCP discussed access and prior auth issues, and showed low interest in the product.",Low,"Access / Prior Auth, Efficacy",Connect with MSL,False,False
CALL_000098,HCP_03538,REP_058,2024-02-27,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,"HCP discussed new indication and study results, showing medium interest.",Medium,"New Indication, Efficacy",Connect with MSL,False,False
CALL_000099,HCP_01422,REP_071,2024-01-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.,"HCP discussed efficacy improvement and formulary restrictions, aligning to wait for formulary decision.",High,"Efficacy, Access / Prior Auth",Wait for formulary decision,False,False
CALL_000100,HCP_04178,REP_018,2024-02-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,"HCP discussed side effect management, cost, and study results, with a medium interest level in the product.",Medium,"Safety, Efficacy",Send clinical reprint,True,False
CALL_000101,HCP_04852,REP_009,2024-01-25,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.,"HCP discussed safety concerns and high cost, aligned on sending clinical reprint.",High,"Safety, Efficacy",Send clinical reprint,False,False
CALL_000102,HCP_00087,REP_077,2024-01-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.,"HCP discussed side effect management, workflow complexity, and study results, with high interest in the product.",High,"Safety, Efficacy",Share copay info,False,False
CALL_000103,HCP_03359,REP_068,2024-01-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,"HCP discussed side effect management, formulary restrictions, and study results, with low interest in the product.",Low,"Safety, Access / Prior Auth",Wait for formulary decision,True,False
CALL_000104,HCP_04205,REP_068,2024-01-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,"HCP discussed efficacy improvement and cost concerns, awaiting formulary decision.",Medium,"Efficacy, Access / Prior Auth",Wait for formulary decision,False,False
CALL_000105,HCP_02178,REP_058,2024-02-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,"HCP discussed access/prior auth, prefers competitor, and has low interest in product.",Low,"Access / Prior Auth, Efficacy",Schedule follow-up visit,False,True
CALL_000106,HCP_01648,REP_054,2024-01-16,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.,"HCP discussed patient support program and study results, aligned on providing starter kits.",High,"Patient Support Program, Efficacy",Provide starter kits,False,False
CALL_000107,HCP_04775,REP_056,2024-02-15,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,"HCP discussed efficacy improvement and needs more data, aligned on sending clinical reprint.",Medium,Efficacy,Send clinical reprint,False,False
CALL_000108,HCP_02496,REP_038,2024-09-13,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,"HCP discussed access and prior auth issues, and aligned on waiting for formulary decision.",Medium,"Access / Prior Auth, Efficacy",Wait for formulary decision,False,False
CALL_000109,HCP_03542,REP_002,2024-01-22,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.,"HCP discussed safety concerns and high cost, aligned on sending clinical reprint.",High,"Safety, Efficacy",Send clinical reprint,False,False
CALL_000110,HCP_02973,REP_011,2024-01-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.,"HCP discussed efficacy improvement and formulary restrictions, aligning on sending clinical reprint.",Medium,"Efficacy, Access / Prior Auth",Send clinical reprint,False,False
CALL_000111,HCP_01600,REP_008,2024-02-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.,"HCP discussed new indication and needs more data, aligned on connecting with MSL.",Medium,"New Indication, Efficacy",Connect with MSL,False,False
CALL_000112,HCP_04735,REP_027,2024-06-06,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.,"HCP discussed access/prior auth and study results, showing low interest in the product.",Low,"Access / Prior Auth, Efficacy",Share copay info,False,False
CALL_000113,HCP_01216,REP_027,2024-01-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.,"HCP discussed side effect management, workflow complexity, and study results, with high interest in the product.",High,"Safety, Efficacy",Wait for formulary decision,False,False
CALL_000114,HCP_02707,REP_032,2024-02-12,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.,"HCP discussed side effect management and needs more data, with low interest level in the product.",Low,"Safety, Efficacy",Schedule follow-up visit,True,False
CALL_000115,HCP_04101,REP_006,2024-01-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.,"HCP discussed safety concerns and workflow complexity, and aligned on providing starter kits.",High,"Safety, Efficacy",Provide starter kits,False,False
CALL_000116,HCP_01249,REP_025,2024-01-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.,"HCP discussed patient support program, study results, and cost concerns, with a medium interest level.",Medium,"Patient Support Program, Efficacy",Send clinical reprint,False,False
CALL_000117,HCP_02098,REP_049,2024-03-26,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,"HCP discussed efficacy improvement and workflow complexity, with high interest level.",High,Efficacy,Schedule follow-up visit,False,False
CALL_000118,HCP_02337,REP_074,2024-02-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,"HCP discussed access and prior auth, and showed high interest in the product.",High,"Access / Prior Auth, Efficacy",Schedule follow-up visit,False,False
CALL_000119,HCP_04873,REP_061,2024-01-17,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,"HCP discussed patient support program and study results, showing low interest.",Low,"Patient Support Program, Efficacy",Schedule follow-up visit,False,False
CALL_000120,HCP_02684,REP_029,2024-02-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,"HCP discussed patient support program and study results, showing medium interest.",Medium,"Patient Support Program, Efficacy",Share copay info,False,False
CALL_000121,HCP_03131,REP_071,2024-02-12,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,"HCP discussed patient support program and study results, showing low interest.",Low,"Patient Support Program, Efficacy",Send clinical reprint,False,False
CALL_000122,HCP_00280,REP_059,2024-02-28,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.,"HCP discussed safety concerns and high product cost, aligning on sending clinical reprints.",High,"Safety, Access / Prior Auth",Send clinical reprint,False,False
CALL_000123,HCP_04834,REP_029,2024-04-04,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned cost too high.,HCP discussed new indication and cost concerns with low interest level,Low,"New Indication, Efficacy",Schedule follow-up visit,False,False
CALL_000124,HCP_01810,REP_057,2024-03-18,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,"HCP discussed patient support program and study results, showing high interest in the product.",High,"Patient Support Program, Efficacy",Provide starter kits,False,False
CALL_000125,HCP_04396,REP_027,2024-01-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.,"HCP discussed safety concerns and workflow complexity, and aligned on sending clinical reprint.",High,"Safety, Efficacy",Send clinical reprint,False,False
CALL_000126,HCP_00476,REP_061,2024-01-17,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.,"HCP discussed side effect management and needs more data, awaiting formulary decision.",Low,"Safety, Efficacy",Wait for formulary decision,False,False
CALL_000127,HCP_01297,REP_016,2024-01-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.,HCP discussed efficacy improvement and study results with high interest level.,High,Efficacy,Share copay info,False,False
CALL_000128,HCP_04385,REP_018,2024-02-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,"HCP discussed safety concerns and workflow complexity, aligning to connect with MSL.",Medium,"Safety, Efficacy",Connect with MSL,False,False
CALL_000129,HCP_01995,REP_012,2024-02-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.,"HCP discussed safety concerns and high cost, showed low interest in the product.",Low,"Safety, Access / Prior Auth",Connect with MSL,False,False
CALL_000130,HCP_00171,REP_028,2024-01-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,HCP raised safety concern and discussed study results,Medium,"Safety, Efficacy",Share copay info,False,False
CALL_000131,HCP_04120,REP_058,2024-01-12,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000132,HCP_04478,REP_000,2024-03-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000133,HCP_02760,REP_031,2024-01-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000134,HCP_01739,REP_011,2024-01-17,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000135,HCP_00642,REP_002,2024-01-03,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000136,HCP_01528,REP_077,2024-01-29,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000137,HCP_00936,REP_046,2024-02-09,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000138,HCP_02017,REP_071,2024-01-06,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000139,HCP_00629,REP_073,2024-01-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000140,HCP_03742,REP_042,2024-05-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000141,HCP_01869,REP_033,2024-04-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000142,HCP_03287,REP_032,2024-03-12,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000143,HCP_02526,REP_054,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000144,HCP_04222,REP_009,2024-01-08,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000145,HCP_02253,REP_034,2024-04-12,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000146,HCP_04714,REP_007,2024-01-10,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000147,HCP_03872,REP_013,2024-01-23,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000148,HCP_04599,REP_042,2024-01-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000149,HCP_02918,REP_068,2024-03-24,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000150,HCP_03667,REP_015,2024-02-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000151,HCP_03329,REP_062,2024-03-13,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000152,HCP_04369,REP_039,2024-01-09,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000153,HCP_00524,REP_077,2024-03-15,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000154,HCP_02156,REP_005,2024-04-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000155,HCP_00145,REP_002,2024-02-12,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000156,HCP_02146,REP_074,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000157,HCP_03465,REP_063,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000158,HCP_00883,REP_060,2024-01-30,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000159,HCP_00579,REP_029,2024-01-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000160,HCP_03735,REP_018,2024-02-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000161,HCP_01569,REP_058,2024-06-25,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000162,HCP_01872,REP_049,2024-01-28,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000163,HCP_04595,REP_061,2024-01-26,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000164,HCP_04654,REP_022,2024-01-17,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000165,HCP_04287,REP_018,2024-02-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000166,HCP_04565,REP_074,2024-04-24,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000167,HCP_00312,REP_055,2024-03-02,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000168,HCP_00955,REP_017,2024-01-21,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000169,HCP_01486,REP_001,2024-01-15,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000170,HCP_03914,REP_021,2024-01-31,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000171,HCP_04320,REP_008,2024-02-25,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000172,HCP_01362,REP_018,2024-01-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000173,HCP_01167,REP_013,2024-02-04,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000174,HCP_01141,REP_024,2024-02-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000175,HCP_00571,REP_074,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000176,HCP_01009,REP_022,2024-03-27,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000177,HCP_03132,REP_071,2024-02-09,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000178,HCP_01663,REP_038,2024-01-26,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000179,HCP_00372,REP_028,2024-01-24,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000180,HCP_03565,REP_052,2024-02-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000181,HCP_02161,REP_037,2024-01-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000182,HCP_00131,REP_065,2024-02-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000183,HCP_01802,REP_013,2024-02-28,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000184,HCP_03136,REP_019,2024-01-05,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000185,HCP_02601,REP_034,2024-03-08,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000186,HCP_04506,REP_032,2024-04-30,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000187,HCP_04966,REP_064,2024-02-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000188,HCP_00252,REP_032,2024-04-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000189,HCP_02707,REP_038,2024-01-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000190,HCP_01529,REP_048,2024-02-22,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000191,HCP_01763,REP_062,2024-03-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000192,HCP_00804,REP_010,2024-06-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000193,HCP_00812,REP_063,2024-03-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000194,HCP_04743,REP_063,2024-02-07,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000195,HCP_04886,REP_022,2024-04-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000196,HCP_01739,REP_041,2024-01-13,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000197,HCP_03352,REP_036,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000198,HCP_01823,REP_036,2024-01-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000199,HCP_03903,REP_064,2024-02-20,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000200,HCP_03714,REP_077,2024-01-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000201,HCP_03168,REP_031,2024-03-03,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000202,HCP_01269,REP_049,2024-01-12,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000203,HCP_01569,REP_022,2024-01-03,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000204,HCP_03910,REP_033,2024-01-19,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000205,HCP_00509,REP_057,2024-01-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000206,HCP_01879,REP_064,2024-01-26,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000207,HCP_01435,REP_069,2024-01-08,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000208,HCP_00991,REP_012,2024-01-13,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000209,HCP_03029,REP_052,2024-02-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000210,HCP_04236,REP_041,2024-05-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000211,HCP_03825,REP_020,2024-01-19,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000212,HCP_00188,REP_030,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000213,HCP_04073,REP_018,2024-01-08,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000214,HCP_02124,REP_068,2024-01-24,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000215,HCP_04906,REP_034,2024-02-27,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000216,HCP_00849,REP_070,2024-01-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000217,HCP_00504,REP_017,2024-01-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000218,HCP_01645,REP_014,2024-03-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000219,HCP_00241,REP_067,2024-04-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000220,HCP_00188,REP_060,2024-01-29,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000221,HCP_02986,REP_036,2024-02-15,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000222,HCP_02534,REP_018,2024-01-24,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000223,HCP_00927,REP_073,2024-01-28,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000224,HCP_03057,REP_062,2024-02-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000225,HCP_04340,REP_023,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000226,HCP_01226,REP_027,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000227,HCP_01716,REP_012,2024-02-07,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000228,HCP_02352,REP_077,2024-02-22,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000229,HCP_02131,REP_053,2024-02-21,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000230,HCP_02117,REP_007,2024-03-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000231,HCP_00985,REP_055,2024-01-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000232,HCP_03821,REP_005,2024-01-22,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000233,HCP_04034,REP_010,2024-03-15,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000234,HCP_01560,REP_062,2024-02-29,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000235,HCP_03731,REP_026,2024-03-10,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.,ERROR,,,,,
CALL_000236,HCP_04875,REP_038,2024-04-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000237,HCP_00235,REP_023,2024-01-06,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000238,HCP_04790,REP_017,2024-01-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000239,HCP_00710,REP_008,2024-05-14,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000240,HCP_01370,REP_023,2024-02-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000241,HCP_01674,REP_042,2024-01-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000242,HCP_02847,REP_053,2024-02-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000243,HCP_00895,REP_055,2024-01-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000244,HCP_04022,REP_003,2024-01-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000245,HCP_03847,REP_048,2024-02-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000246,HCP_02784,REP_029,2024-04-19,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000247,HCP_01575,REP_036,2024-02-08,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000248,HCP_03783,REP_049,2024-03-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000249,HCP_01463,REP_072,2024-01-15,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000250,HCP_02245,REP_018,2024-03-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000251,HCP_01829,REP_014,2024-01-04,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000252,HCP_04442,REP_015,2024-02-05,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000253,HCP_03603,REP_071,2024-01-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000254,HCP_00550,REP_052,2024-03-24,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000255,HCP_01075,REP_004,2024-02-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000256,HCP_01590,REP_025,2024-01-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000257,HCP_04166,REP_058,2024-01-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000258,HCP_04577,REP_020,2024-02-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000259,HCP_01950,REP_011,2024-01-25,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.,ERROR,,,,,
CALL_000260,HCP_04223,REP_028,2024-01-04,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000261,HCP_03433,REP_052,2024-02-25,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000262,HCP_02848,REP_058,2024-02-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000263,HCP_04208,REP_017,2024-01-25,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000264,HCP_00073,REP_009,2024-02-28,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000265,HCP_03470,REP_074,2024-02-10,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000266,HCP_04271,REP_022,2024-01-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000267,HCP_01447,REP_037,2024-01-13,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000268,HCP_02950,REP_043,2024-01-22,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000269,HCP_04688,REP_026,2024-02-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000270,HCP_03009,REP_052,2024-01-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000271,HCP_04363,REP_043,2024-02-18,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000272,HCP_01041,REP_007,2024-05-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000273,HCP_03587,REP_007,2024-08-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000274,HCP_02603,REP_013,2024-01-08,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000275,HCP_04539,REP_010,2024-02-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000276,HCP_04314,REP_048,2024-01-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000277,HCP_01527,REP_064,2024-01-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000278,HCP_02715,REP_021,2024-03-31,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000279,HCP_00371,REP_012,2024-02-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000280,HCP_04116,REP_020,2024-01-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000281,HCP_04841,REP_030,2024-01-06,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000282,HCP_02238,REP_042,2024-02-22,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000283,HCP_02733,REP_035,2024-01-03,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000284,HCP_03481,REP_016,2024-01-15,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000285,HCP_04623,REP_068,2024-04-20,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000286,HCP_03517,REP_063,2024-01-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000287,HCP_01357,REP_000,2024-03-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000288,HCP_02665,REP_046,2024-01-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000289,HCP_01469,REP_066,2024-01-01,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000290,HCP_03125,REP_072,2024-01-23,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000291,HCP_03316,REP_062,2024-02-10,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000292,HCP_01483,REP_076,2024-03-13,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000293,HCP_03864,REP_013,2024-04-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000294,HCP_03834,REP_035,2024-01-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000295,HCP_03993,REP_012,2024-02-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000296,HCP_02106,REP_038,2024-01-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000297,HCP_04090,REP_033,2024-05-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000298,HCP_03053,REP_034,2024-01-31,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000299,HCP_02349,REP_065,2024-01-12,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000300,HCP_01998,REP_034,2024-01-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000301,HCP_00505,REP_074,2024-03-09,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000302,HCP_02728,REP_031,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000303,HCP_04730,REP_006,2024-01-15,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000304,HCP_01119,REP_055,2024-03-12,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000305,HCP_02701,REP_027,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000306,HCP_02237,REP_016,2024-02-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000307,HCP_01953,REP_007,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000308,HCP_02317,REP_045,2024-01-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000309,HCP_02431,REP_043,2024-01-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000310,HCP_04762,REP_075,2024-01-04,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000311,HCP_04058,REP_068,2024-01-04,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000312,HCP_03846,REP_046,2024-03-13,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000313,HCP_03470,REP_066,2024-02-15,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000314,HCP_04006,REP_069,2024-01-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000315,HCP_02574,REP_003,2024-02-14,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000316,HCP_02414,REP_008,2024-07-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000317,HCP_02551,REP_054,2024-03-07,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000318,HCP_01240,REP_005,2024-01-07,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000319,HCP_03733,REP_033,2024-04-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000320,HCP_01059,REP_046,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000321,HCP_01427,REP_070,2024-04-07,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000322,HCP_04851,REP_002,2024-01-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000323,HCP_02963,REP_028,2024-01-04,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000324,HCP_04950,REP_058,2024-01-16,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000325,HCP_00937,REP_043,2024-01-31,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000326,HCP_00334,REP_026,2024-06-08,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000327,HCP_01615,REP_055,2024-01-16,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000328,HCP_01599,REP_047,2024-04-13,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000329,HCP_04517,REP_072,2024-02-16,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000330,HCP_01634,REP_047,2024-01-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000331,HCP_02146,REP_069,2024-01-16,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000332,HCP_01361,REP_054,2024-01-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000333,HCP_01257,REP_056,2024-01-31,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000334,HCP_02238,REP_027,2024-02-26,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000335,HCP_03517,REP_017,2024-01-24,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000336,HCP_02027,REP_052,2024-08-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000337,HCP_03421,REP_045,2024-02-29,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000338,HCP_02170,REP_074,2024-04-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000339,HCP_00312,REP_007,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000340,HCP_02395,REP_075,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000341,HCP_04877,REP_027,2024-01-01,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000342,HCP_03111,REP_002,2024-01-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000343,HCP_04654,REP_022,2024-01-30,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000344,HCP_02750,REP_068,2024-03-23,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000345,HCP_01235,REP_041,2024-03-05,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000346,HCP_02499,REP_059,2024-01-17,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000347,HCP_02277,REP_073,2024-03-31,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000348,HCP_01228,REP_000,2024-06-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000349,HCP_01178,REP_057,2024-01-02,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000350,HCP_00691,REP_048,2024-01-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000351,HCP_00862,REP_053,2024-01-16,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000352,HCP_00814,REP_040,2024-01-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000353,HCP_01599,REP_053,2024-03-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000354,HCP_04824,REP_073,2024-03-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000355,HCP_04224,REP_030,2024-01-21,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000356,HCP_03265,REP_058,2024-02-23,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000357,HCP_04094,REP_049,2024-02-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000358,HCP_04082,REP_011,2024-02-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000359,HCP_03027,REP_050,2024-02-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000360,HCP_04112,REP_041,2024-01-09,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000361,HCP_02210,REP_077,2024-02-12,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000362,HCP_02230,REP_056,2024-02-20,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000363,HCP_01225,REP_035,2024-01-20,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000364,HCP_00692,REP_054,2024-01-26,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000365,HCP_00192,REP_020,2024-05-29,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000366,HCP_01873,REP_065,2024-03-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000367,HCP_01290,REP_024,2024-04-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000368,HCP_04491,REP_059,2024-01-14,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000369,HCP_01011,REP_038,2024-01-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000370,HCP_01879,REP_074,2024-01-13,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000371,HCP_00743,REP_014,2024-01-22,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000372,HCP_03034,REP_027,2024-02-17,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000373,HCP_03962,REP_023,2024-02-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000374,HCP_04594,REP_076,2024-05-17,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000375,HCP_04786,REP_011,2024-01-22,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000376,HCP_04579,REP_065,2024-05-20,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000377,HCP_01225,REP_013,2024-01-10,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000378,HCP_00314,REP_076,2024-01-03,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000379,HCP_04433,REP_032,2024-02-07,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000380,HCP_04177,REP_011,2024-01-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000381,HCP_03500,REP_035,2024-05-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000382,HCP_02349,REP_021,2024-06-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000383,HCP_04071,REP_020,2024-01-15,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000384,HCP_04189,REP_050,2024-01-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000385,HCP_02271,REP_032,2024-01-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000386,HCP_02615,REP_067,2024-02-16,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000387,HCP_01831,REP_028,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000388,HCP_03941,REP_032,2024-05-15,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000389,HCP_00024,REP_033,2024-01-09,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000390,HCP_03416,REP_054,2024-01-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000391,HCP_04580,REP_012,2024-01-03,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000392,HCP_03070,REP_054,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000393,HCP_02693,REP_075,2024-02-04,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000394,HCP_02249,REP_022,2024-05-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000395,HCP_04060,REP_021,2024-05-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000396,HCP_02957,REP_060,2024-02-11,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000397,HCP_04760,REP_069,2024-01-15,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000398,HCP_02202,REP_017,2024-01-25,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000399,HCP_03575,REP_064,2024-01-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000400,HCP_02902,REP_020,2024-01-19,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000401,HCP_01951,REP_069,2024-05-25,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000402,HCP_04707,REP_057,2024-02-07,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000403,HCP_04423,REP_000,2024-01-13,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000404,HCP_02548,REP_078,2024-01-06,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000405,HCP_02668,REP_032,2024-02-05,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000406,HCP_02793,REP_076,2024-01-04,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000407,HCP_00810,REP_038,2024-01-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000408,HCP_01437,REP_045,2024-02-19,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000409,HCP_02206,REP_052,2024-01-03,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000410,HCP_02270,REP_018,2024-02-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000411,HCP_03978,REP_048,2024-01-26,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000412,HCP_02052,REP_021,2024-01-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000413,HCP_03546,REP_079,2024-02-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000414,HCP_00542,REP_046,2024-03-20,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000415,HCP_00599,REP_042,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000416,HCP_04398,REP_019,2024-01-09,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000417,HCP_01792,REP_021,2024-04-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000418,HCP_03125,REP_019,2024-01-09,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000419,HCP_02896,REP_040,2024-01-18,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000420,HCP_04592,REP_042,2024-01-06,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000421,HCP_02001,REP_059,2024-01-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000422,HCP_00134,REP_076,2024-01-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000423,HCP_02780,REP_079,2024-02-06,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000424,HCP_03604,REP_012,2024-01-21,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000425,HCP_03825,REP_019,2024-02-18,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.,ERROR,,,,,
CALL_000426,HCP_02971,REP_056,2024-01-13,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000427,HCP_00786,REP_023,2024-01-27,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000428,HCP_01597,REP_061,2024-01-20,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000429,HCP_00844,REP_068,2024-02-09,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000430,HCP_02194,REP_018,2024-02-25,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000431,HCP_01630,REP_060,2024-01-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000432,HCP_03574,REP_004,2024-02-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000433,HCP_02550,REP_039,2024-01-15,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000434,HCP_00678,REP_009,2024-02-10,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000435,HCP_04476,REP_003,2024-01-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000436,HCP_02101,REP_077,2024-01-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000437,HCP_03076,REP_032,2024-01-02,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000438,HCP_00635,REP_079,2024-01-04,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000439,HCP_03975,REP_004,2024-05-06,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000440,HCP_04493,REP_040,2024-02-17,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000441,HCP_02284,REP_067,2024-07-07,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000442,HCP_00440,REP_041,2024-02-29,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000443,HCP_00489,REP_008,2024-01-05,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000444,HCP_01521,REP_043,2024-01-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000445,HCP_04396,REP_060,2024-01-01,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.,ERROR,,,,,
CALL_000446,HCP_01678,REP_057,2024-01-13,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000447,HCP_02828,REP_038,2024-05-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000448,HCP_03604,REP_028,2024-01-31,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000449,HCP_02439,REP_040,2024-01-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000450,HCP_00913,REP_046,2024-01-03,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000451,HCP_02379,REP_059,2024-01-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000452,HCP_04638,REP_011,2024-01-04,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000453,HCP_01200,REP_051,2024-01-21,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000454,HCP_02487,REP_007,2024-02-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000455,HCP_02325,REP_065,2024-01-30,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000456,HCP_00324,REP_041,2024-01-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000457,HCP_00947,REP_053,2024-02-25,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000458,HCP_03160,REP_009,2024-01-24,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000459,HCP_00444,REP_035,2024-01-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000460,HCP_04965,REP_024,2024-01-22,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000461,HCP_04600,REP_033,2024-01-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000462,HCP_02799,REP_011,2024-04-06,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000463,HCP_00492,REP_022,2024-01-04,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000464,HCP_02479,REP_017,2024-01-30,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000465,HCP_04585,REP_071,2024-01-30,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000466,HCP_04394,REP_078,2024-01-26,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000467,HCP_04324,REP_044,2024-01-07,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000468,HCP_03461,REP_048,2024-02-25,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000469,HCP_01245,REP_006,2024-03-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000470,HCP_02970,REP_044,2024-01-22,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000471,HCP_00928,REP_058,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000472,HCP_04120,REP_079,2024-01-25,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000473,HCP_03203,REP_076,2024-01-11,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.,ERROR,,,,,
CALL_000474,HCP_02687,REP_045,2024-01-17,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000475,HCP_04954,REP_033,2024-01-20,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000476,HCP_00156,REP_036,2024-01-05,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000477,HCP_01876,REP_021,2024-01-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000478,HCP_00215,REP_045,2024-03-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.,ERROR,,,,,
CALL_000479,HCP_01981,REP_028,2024-01-09,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000480,HCP_02592,REP_003,2024-01-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000481,HCP_03830,REP_078,2024-02-07,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000482,HCP_01107,REP_026,2024-02-24,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000483,HCP_01015,REP_078,2024-01-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000484,HCP_02845,REP_067,2024-03-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000485,HCP_04282,REP_076,2024-01-18,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000486,HCP_00068,REP_006,2024-01-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000487,HCP_02229,REP_072,2024-02-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000488,HCP_04456,REP_003,2024-02-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000489,HCP_01726,REP_005,2024-05-26,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000490,HCP_04653,REP_028,2024-01-25,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000491,HCP_01772,REP_025,2024-01-05,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000492,HCP_02645,REP_061,2024-03-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000493,HCP_04790,REP_060,2024-01-06,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.,ERROR,,,,,
CALL_000494,HCP_00722,REP_047,2024-01-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000495,HCP_01194,REP_074,2024-01-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000496,HCP_04638,REP_069,2024-09-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000497,HCP_01193,REP_001,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.,ERROR,,,,,
CALL_000498,HCP_04384,REP_036,2024-01-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000499,HCP_03801,REP_052,2024-01-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000500,HCP_03943,REP_028,2024-05-28,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000501,HCP_04982,REP_040,2024-06-17,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.,ERROR,,,,,
CALL_000502,HCP_00070,REP_057,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000503,HCP_04418,REP_005,2024-01-22,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000504,HCP_04296,REP_074,2024-01-31,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000505,HCP_04601,REP_018,2024-01-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000506,HCP_00860,REP_069,2024-03-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000507,HCP_04902,REP_056,2024-01-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000508,HCP_03953,REP_022,2024-01-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.,ERROR,,,,,
CALL_000509,HCP_02008,REP_075,2024-01-19,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000510,HCP_03670,REP_066,2024-01-06,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000511,HCP_00639,REP_049,2024-01-18,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000512,HCP_03191,REP_003,2024-01-03,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000513,HCP_02926,REP_024,2024-02-21,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000514,HCP_00366,REP_034,2024-03-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000515,HCP_03580,REP_073,2024-02-20,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000516,HCP_04235,REP_067,2024-05-05,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.,"HCP raised safety concern, prefers competitor, and has low interest in product.",Low,"Safety, Access / Prior Auth",Share copay info,True,True
CALL_000517,HCP_01027,REP_017,2024-01-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000518,HCP_03510,REP_075,2024-01-15,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000519,HCP_04492,REP_065,2024-01-25,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000520,HCP_04605,REP_078,2024-04-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.,ERROR,,,,,
CALL_000521,HCP_04811,REP_026,2024-02-09,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000522,HCP_04725,REP_022,2024-03-08,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000523,HCP_03691,REP_013,2024-03-03,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000524,HCP_03996,REP_019,2024-01-25,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000525,HCP_01843,REP_049,2024-01-25,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000526,HCP_03819,REP_029,2024-02-19,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000527,HCP_03130,REP_078,2024-03-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.,ERROR,,,,,
CALL_000528,HCP_04531,REP_002,2024-01-04,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.,ERROR,,,,,
CALL_000529,HCP_03755,REP_059,2024-01-04,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000530,HCP_01225,REP_039,2024-01-03,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000531,HCP_01204,REP_067,2024-03-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000532,HCP_01128,REP_030,2024-02-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000533,HCP_04825,REP_075,2024-01-19,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000534,HCP_04337,REP_022,2024-01-29,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000535,HCP_01156,REP_023,2024-01-22,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000536,HCP_04233,REP_011,2024-03-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000537,HCP_01246,REP_007,2024-01-14,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000538,HCP_02741,REP_011,2024-01-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000539,HCP_03507,REP_071,2024-01-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000540,HCP_01308,REP_031,2024-02-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000541,HCP_04099,REP_054,2024-02-25,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000542,HCP_02484,REP_046,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000543,HCP_03454,REP_047,2024-01-31,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.,ERROR,,,,,
CALL_000544,HCP_03368,REP_044,2024-01-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000545,HCP_00714,REP_028,2024-01-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000546,HCP_01161,REP_048,2024-01-29,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000547,HCP_04867,REP_046,2024-01-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000548,HCP_02631,REP_024,2024-02-11,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000549,HCP_01169,REP_007,2024-02-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000550,HCP_03918,REP_051,2024-01-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.,ERROR,,,,,
CALL_000551,HCP_01992,REP_043,2024-02-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000552,HCP_02870,REP_009,2024-03-24,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000553,HCP_02724,REP_066,2024-03-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.,ERROR,,,,,
CALL_000554,HCP_00377,REP_064,2024-05-12,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000555,HCP_02190,REP_056,2024-02-10,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000556,HCP_00569,REP_033,2024-01-05,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.,ERROR,,,,,
CALL_000557,HCP_03369,REP_024,2024-05-07,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000558,HCP_02908,REP_035,2024-01-28,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000559,HCP_01421,REP_000,2024-01-17,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000560,HCP_00746,REP_078,2024-01-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.,ERROR,,,,,
CALL_000561,HCP_04106,REP_013,2024-03-21,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.,ERROR,,,,,
CALL_000562,HCP_00976,REP_054,2024-01-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000563,HCP_00033,REP_051,2024-04-10,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.,ERROR,,,,,
CALL_000564,HCP_00077,REP_022,2024-02-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000565,HCP_04685,REP_016,2024-01-18,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000566,HCP_02083,REP_014,2024-01-12,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000567,HCP_03547,REP_010,2024-01-01,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000568,HCP_04671,REP_039,2024-01-26,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.,ERROR,,,,,
CALL_000569,HCP_01803,REP_027,2024-02-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000570,HCP_01749,REP_038,2024-01-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.,ERROR,,,,,
CALL_000571,HCP_01411,REP_053,2024-01-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000572,HCP_03808,REP_048,2024-01-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000573,HCP_03396,REP_049,2024-01-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000574,HCP_02656,REP_004,2024-03-12,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.,ERROR,,,,,
CALL_000575,HCP_04851,REP_010,2024-01-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000576,HCP_01084,REP_030,2024-03-13,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000577,HCP_04872,REP_068,2024-01-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000578,HCP_01516,REP_057,2024-03-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.,ERROR,,,,,
CALL_000579,HCP_00932,REP_047,2024-01-31,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000580,HCP_04038,REP_072,2024-02-25,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.,ERROR,,,,,
CALL_000581,HCP_00406,REP_047,2024-02-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000582,HCP_01912,REP_044,2024-01-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000583,HCP_04880,REP_063,2024-03-14,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000584,HCP_00092,REP_072,2024-04-30,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000585,HCP_04476,REP_030,2024-01-05,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000586,HCP_01639,REP_042,2024-05-02,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.,ERROR,,,,,
CALL_000587,HCP_04480,REP_051,2024-01-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000588,HCP_00188,REP_009,2024-02-13,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000589,HCP_01747,REP_063,2024-02-24,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.,ERROR,,,,,
CALL_000590,HCP_01758,REP_040,2024-01-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000591,HCP_01999,REP_016,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.,ERROR,,,,,
CALL_000592,HCP_03115,REP_018,2024-01-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000593,HCP_02222,REP_033,2024-04-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.,ERROR,,,,,
CALL_000594,HCP_03729,REP_057,2024-01-28,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.,ERROR,,,,,
CALL_000595,HCP_03930,REP_038,2024-01-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.,ERROR,,,,,
CALL_000596,HCP_02545,REP_038,2024-01-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.,ERROR,,,,,
CALL_000597,HCP_02025,REP_058,2024-01-31,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.,ERROR,,,,,
CALL_000598,HCP_00341,REP_064,2024-01-25,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.,ERROR,,,,,
CALL_000599,HCP_02198,REP_034,2024-02-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.,ERROR,,,,,
CALL_000600,HCP_02813,REP_000,2024-04-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.,ERROR,,,,,
CALL_000601,HCP_04631,REP_074,2024-02-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.,ERROR,,,,,
CALL_000602,HCP_01967,REP_027,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.,ERROR,,,,,
